Dr. Jorge Cortes discusses new data on bosutinib, a new tyrosine kinase inhibitor for CML.
FDA Updates Fludarabine Phosphate Labeling in Chronic Lymphocytic Leukemia
The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.
Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy
Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.
Revumenib Elicits Favorable Efficacy in mNPM1 Acute Myeloid Leukemia
Developers are expected to file a supplemental NDA for revumenib in NPM1-mutated AML in the first half of 2025.
Immunotherapy Approaches in AML
Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.
Determining the Next Steps Forward With BTK Inhibitors in Relapsed CLL
Nicole Lamanna, MD, discusses addressing a clinically unmet need among patients with CLL who have relapsed on multiple prior lines of therapy.
FDA Approves Obecabtagene Autoleucel in B-Cell ALL
Results from the FELIX trial support the approval of obecabtagene autoleucel in B-cell ALL.
